[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Cao, W., Chen, H.D., Yu, Y.W., et al. (2021) Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020. Chinese Medical Journal, 134, 783-791.
https://doi.org/10.1097/CM9.0000000000001474
|
[3]
|
Morgan, E., Soerjomataram, I., Rumgay, H., et al. (2022) The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortal-ity in 2020 and Projections to 2040: New Estimates from GLOBOCAN 2020. Gastroenterology, 163, 649-658.E2. https://doi.org/10.1053/j.gastro.2022.05.054
|
[4]
|
杨欢, 孙宛怡, 王建炳, 等. 中国食管癌病因学、筛查及早期诊断研究进展[J]. 肿瘤防治研究, 2022, 49(3): 169-175.
|
[5]
|
王志鹏, 张海平, 宗亮, 等. 新疆地区食管癌发病风险的病例对照研究[J]. 中国肿瘤临床, 2017, 44(2): 92-95.
|
[6]
|
Uhlenhopp, D.J., Then, E.O., Sunkara, T., et al. (2020) Epidemiology of Esophageal Cancer: Update in Global Trends, Etiology and Risk Factors. Clinical Journal of Gastroenterology, 13, 1010-1021.
https://doi.org/10.1007/s12328-020-01237-x
|
[7]
|
Kakeji, Y., Oshikiri, T., Takiguchi, G., et al. (2021) Multimodal-ity Approaches to Control Esophageal Cancer: Development of Chemoradiotherapy, Chemotherapy, and Immunotherapy. Esophagus, 18, 25-32.
https://doi.org/10.1007/s10388-020-00782-1
|
[8]
|
Obermannová, R., Alsina, M., Cervantes, A., et al. (2022) Oe-sophageal Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 33, 992-1004. https://doi.org/10.1016/j.annonc.2022.07.003
|
[9]
|
Huang, T.X. and Fu, L. (2019) The Immune Land-scape of Esophageal Cancer. Cancer Communications, 39, Article No. 79. https://doi.org/10.1186/s40880-019-0427-z
|
[10]
|
Lin, E.W., Karakasheva, T.A., Hicks, P.D., et al. (2016) The Tu-mor Microenvironment in Esophageal Cancer. Oncogene, 35, 5337-5349. https://doi.org/10.1038/onc.2016.34
|
[11]
|
Whiteside, T.L. (2008) The Tumor Microenvironment and Its Role in Promoting Tumor Growth. Oncogene, 27, 5904-5912. https://doi.org/10.1038/onc.2008.271
|
[12]
|
Farhood, B., Najafi, M. and Mortezaee, K. (2019) CD8+ Cytotoxic T Lymphocytes in Cancer Immunotherapy: A Review. Journal of Cellular Physiology, 234, 8509-8521. https://doi.org/10.1002/jcp.27782
|
[13]
|
Zhou, N. and Hofstetter, W.L. (2020) Prognostic and Therapeutic Molecular Markers in the Clinical Management of Esophageal Cancer. Expert Review of Mo-lecular Diagnostics, 20, 401-411.
https://doi.org/10.1080/14737159.2020.1731307
|
[14]
|
Choi, Y., Shi, Y., Haymaker, C.L., et al. (2020) T-Cell Ago-nists in Cancer Immunotherapy. Journal for ImmunoTherapy of Cancer, 8, e000966. https://doi.org/10.1136/jitc-2020-000966
|
[15]
|
Campana, D., Schwarz, H. and Imai, C. (2014) 4-1BB Chimeric An-tigen Receptors. The Cancer Journal, 20, 134-140.
https://doi.org/10.1097/PPO.0000000000000028
|
[16]
|
Jin, X., Xu, Q., Pu, C., et al. (2021) Therapeutic Efficacy of Anti-CD19 CAR-T Cells in a Mouse Model of Systemic Lupus Erythematosus. Cellular & Molecular Immunology, 18, 1896-1903. https://doi.org/10.1038/s41423-020-0472-1
|
[17]
|
Panneton, V., Chang, J., Witalis, M., et al. (2019) Inducible T-Cell Co-Stimulator: Signaling Mechanisms in T Follicular Helper Cells and beyond. Immunological Reviews, 291, 91-103. https://doi.org/10.1111/imr.12771
|
[18]
|
Solinas, C., Gu-Trantien, C. and Willard-Gallo, K. (2020) The Rationale behind Targeting the ICOS-ICOS Ligand Costimulatory Pathway in Cancer Immunotherapy. ESMO Open, 5, e000544.
https://doi.org/10.1136/esmoopen-2019-000544
|
[19]
|
Zou, L.Q., Yang, X., Li, Y.D. and Zhu, Z.F. (2019) Immune Checkpoint Inhibitors: A New Era for Esophageal Cancer. Expert Review of Anticancer Therapy, 19, 731-738. https://doi.org/10.1080/14737140.2019.1654379
|
[20]
|
Dhupar, R., Van Der Kraak, L., Pennathur, A., et al. (2017) Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor. The Annals of Thoracic Surgery, 103, 1340-1349.
https://doi.org/10.1016/j.athoracsur.2016.12.011
|
[21]
|
O’Neill, R.E. and Cao, X. (2019) Co-Stimulatory and Co-Inhibitory Pathways in Cancer Immunotherapy. Advances in Cancer Research, 143, 145-194. https://doi.org/10.1016/bs.acr.2019.03.003
|
[22]
|
Xie, F., Xu, M., Lu, J., et al. (2019) The Role of Exosomal PD-L1 in Tumor Progression and Immunotherapy. Molecular Cancer, 18, Article No. 146. https://doi.org/10.1186/s12943-019-1074-3
|
[23]
|
Gubin, M.M., Zhang, X., Schuster, H., et al. (2014) Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens. Nature, 515, 577-581. https://doi.org/10.1038/nature13988
|
[24]
|
Guo, W., Wang, P., Li, N., et al. (2018) Prognostic Value of PD-L1 in Esophageal Squamous Cell Carcinoma: A Meta-Analysis. Oncotarget, 9, 13920-13933. https://doi.org/10.18632/oncotarget.23810
|
[25]
|
Okadome, K., Baba, Y., Nomoto, D., et al. (2020) Prognostic and Clinical Impact of PD-L2 and PD-L1 Expression in a Cohort of 437 Oesophageal Cancers. British Journal of Cancer, 122, 1535-1543.
https://doi.org/10.1038/s41416-020-0811-0
|
[26]
|
Baba, Y., Yagi, T., Kosumi, K., et al. (2019) Morphological Lymphocytic Reaction, Patient Prognosis and PD-1 Expression after Surgical Resection for Oesophageal Cancer. British Journal of Surgery, 106, 1352-1361.
https://doi.org/10.1002/bjs.11301
|
[27]
|
Amatore, F., Gorvel, L. and Olive, D. (2020) Role of Inducible Co-Stimulator (ICOS) in Cancer Immunotherapy. Expert Opinion on Biological Therapy, 20, 141-150. https://doi.org/10.1080/14712598.2020.1693540
|
[28]
|
Edwards, J., Tasker, A., Pires Da Silva, I., et al. (2019) Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets across Longitudinal Specimens in Treat-ment-Naïve Melanoma Patients: Implications for Clinical Trials. Clinical Cancer Research, 25, 3247-3258. https://doi.org/10.1158/1078-0432.CCR-18-4011
|
[29]
|
Nagase, H., Takeoka, T., Urakawa, S., et al. (2017) ICOS+ Foxp3+ TILs in Gastric Cancer Are Prognostic Markers and Effector Regulatory T Cells Associated with Helicobacter Pylori. International Journal of Cancer, 140, 686-695.
https://doi.org/10.1002/ijc.30475
|
[30]
|
Zappasodi, R., Sirard, C., Li, Y., et al. (2019) Rational Design of An-ti-GITR-Based Combination Immunotherapy. Nature Medicine, 25, 759-766. https://doi.org/10.1038/s41591-019-0420-8
|
[31]
|
Hong, M.H., Shin, S.J., Shin, S.K., et al. (2019) High CD3 and ICOS and Low TIM-3 Expression Predict Favourable Survival in Resected Oesophageal Squamous Cell Carcinoma. Scientific Reports, 9, Article No. 20197.
https://doi.org/10.1038/s41598-019-56828-7
|
[32]
|
Chester, C., Sanmamed, M.F., Wang, J., et al. (2018) Immuno-therapy Targeting 4-1BB: Mechanistic Rationale, Clinical Results, and Future Strategies. Blood, 131, 49-57. https://doi.org/10.1182/blood-2017-06-741041
|
[33]
|
Wilcox, R, A., Tamada, K., Flies, D, B., et al. (2004) Ligation of CD137 Receptor Prevents and Reverses Established Anergy of CD8+ Cytolytic T Lymphocytes in Vivo. Blood, 103, 177-184. https://doi.org/10.1182/blood-2003-06-2184
|
[34]
|
Menk, A.V., Scharping, N.E., Rivadeneira, D.B., et al. (2018) 4-1BB Costimulation Induces T Cell Mitochondrial Function and Biogenesis Enabling Cancer Immunotherapeutic Responses. Journal of Experimental Medicine, 215, 1091-1100. https://doi.org/10.1084/jem.20171068
|
[35]
|
Williams, J.B., Horton, B.L., Zheng, Y., et al. (2017) The EGR2 Tar-gets LAG-3 and 4-1BB Describe and Regulate Dysfunctional Antigen-Specific CD8+ T Cells in the Tumor Microenvi-ronment. The Journal of Experimental Medicine, 214, 381-400. https://doi.org/10.1084/jem.20160485
|
[36]
|
Newcomb, E.W., et al. (2010) Radiotherapy Enhances Antitumor Effect of Anti-CD137 Therapy in a Mouse Glioma Model. Radiation Research, 173, 426-432.
|